Faeth Therapeutics, Inc. has announced positive preliminary results from its Phase 2 clinical trial of PIKTOR, a drug aimed at treating advanced endometrial cancer. The results show a confirmed objective response rate of 33% among patients, which is significant as the company seeks to advance to Phase 3 trials. This development is crucial for Faeth as it positions itself in a competitive oncology market.

Background

Faeth Therapeutics, Inc. is a clinical-stage oncology company focused on developing innovative therapies for cancer patients. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. Faeth trades on the Nasdaq under the ticker symbol FTH. Recent filings include a Form 4 on November 3, 2026, and a Form 10-Q on the same date, indicating ongoing corporate activity.

What the Filing Says

In its recent SEC filing, Faeth disclosed that on November 9, 2026, it issued a press release detailing the topline results from the Phase 2 trial of PIKTOR. The trial, known as PIK-201, showed a confirmed objective response rate of 33% in efficacy-evaluable patients, with a disease control rate of 83%. The trial included patients who had previously undergone at least one line of therapy.

Impact

The positive results from the Phase 2 trial may influence healthcare providers and patients dealing with advanced endometrial cancer. The data suggests that PIKTOR could offer a new treatment option in a market where existing therapies are limited. The findings are expected to attract attention from oncologists and potentially lead to increased investment in Faeth's ongoing research and development efforts.

What's Next

Faeth Therapeutics plans to advance PIKTOR into a Phase 3 registrational trial, pending regulatory alignment. The company aims to expedite the process of bringing this promising treatment to patients who have limited options available.